Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant’s blood-based colon cancer screening test.

The post Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test appeared first on Investor’s Business Daily.